Company: CORT
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001628280-25-019942
Chunk: 27

Company: CORCEPT THERAPEUTICS INC
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 27
---
              |           |     | Approximate Increase 
 (%)                  |
|:-------------------------|:----|:-----------------|----------:|:----|:-----------------|----------:|:----|:---------------------|
| Joseph K. Belanoff, M.D. |     | $                | 1,100,000 |     | $                | 1,144,000 |     | 4.0%                 |
| William Guyer, Pharm.D.  |     | $                |   633,000 |     | $                |   658,320 |     | 4.0%                 |
| Sean Maduck              |     | $                |   604,000 |     | $                |   628,161 |     | 4.0%                 |
| Atabak Mokari            |     | $                |   527,000 |     | $                |   548,080 |     | 4.0%                 |
| Charles Robb             |     | $                |   662,000 |     | $                |   688,480 |     | 4.0%                 |

Performance-Based Compensation

Cash Bonus. We pay discretionary bonuses annually based on the Compensation Committee’s assessment of our prior year’s progress toward achieving significant long-term goals and the contribution to such achievements by each named executive officer. We also may pay bonuses when significant goals are met.

Factors considered may include successful completion of a clinical trial, approval of a new product, a significant increase in revenue or profitability or substantial improvements in our management or operational capabilities. The discretionary bonuses incentivize achievement of our near-term objectives, consistent with our long-term goals.

Target annual bonuses for our named executive officers are set as a percentage of their salaries and designed to be market competitive and allow us to attract and retain talent. The Compensation Committee determines, in its sole discretion, each year’s actual bonus amounts, based on its evaluation of company-wide and individual performance. For 2024, the target annual bonuses for our named executive officers remained the same as in 2023 and were 100 percent of salary for Dr. Belanoff and 50 percent of salary for Dr. Guyer and Messrs. Maduck, Mokari and Robb.

In February 2025, the Compensation Committee evaluated the contributions of each of our named executive officers with respect to progress towards the achievement of our long-term goals and identified the accomplishments set forth in the Executive Summary